HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Rani Therapeutics Holdings (NASDAQ:RANI) but lowered the price target from $13 to $9.
August 16, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Rani Therapeutics Holdings but lowered the price target from $13 to $9.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook on its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100